Long‑term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: Treatment persistence is differentially affected by disease phenotype, obesity and sex
Arthritis Research & Therapy 2025;27:202 Doi: 10.1186/s13075-025-03664-y
Data by Flouri et al. support greater drug persistence with secukinumab than with TNF inhibitors in patients with axSpA and peripheral spondyloarthritis, both with respect to efficacy- and safety-related discontinuations, while the achievement of 6-month treatment targets was comparable. Flouri et al. compared long term treatment persistence, efficacy and safety between secukinumab and TNF inhibitors in a cohort of patients with SpA treated in real life.